Erlotinib [25 mg, 100 mg, 150 mg Film-Coated Tablet] for the treatment of locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with activating Epidermal Growth Factor Receptor (EGFR) mutations
Cycle 4 | DrugsHTA Council Recommendation (as of 12 March 2026)
As a final recommendation, the HTA Council recommends the government financing of erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet) for first-line therapy of patients with EGFR-positive advanced or metastatic NSCLC. Erlotinib is recommended for EGFR exon 19 deletion or exon 21 L858R mutation. Additionally, it is an option for EGFR S768I, L861Q, and/or G719X mutations.
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet) for first-line therapy of patients with EGFR-positive advanced or metastatic NSCLC be funded by the government?
- Secretary of Health Decision: Approved as of 30 April 2026
Evidence and Relevant Documents